Jae W Lee1, Michael Koeppen, Seong-Wook Seo, Jessica L Bowser, Xiaoyi Yuan, Jiwen Li, Maria Sibilia, Amrut V Ambardekar, Xu Zhang, Tobias Eckle, Seung-Hee Yoo, Holger K Eltzschig. 1. From the Department of Anesthesiology, The University of Texas Health Science Center at Houston, McGovern Medical School, Houston, Texas (J.W.L., J.L.B., X.Y., J.L., H.K.E.) Department of Anesthesiology and Intensive Care Medicine, Tübingen University Hospital, Eberhard-Karls University Tübingen, Tübingen, Germany (M.K.) Department of Anesthesiology, University of New Mexico School of Medicine, Albuquerque, New Mexico (S.-W.S.) Department of Cardiac Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China (J.L.) Institute for Cancer Research, Department of Medicine, Medical University of Vienna, Vienna, Austria (M.S.) Division of Cardiology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado (A.V.A.) Center for Clinical and Translational Sciences, The University of Texas Health Science Center at Houston, Houston, Texas (X.Z.) Department of Anesthesiology, University of Colorado School of Medicine, Aurora, Colorado (T.E.) Department of Biochemistry and Molecular Biology, The University of Texas Health Science Center at Houston, McGovern Medical School, Houston, Texas (S.-H.Y.).
Abstract
BACKGROUND: During myocardial ischemia, hypoxia-inducible factors are stabilized and provide protection from ischemia and reperfusion injury. Recent studies show that myocyte-specific hypoxia-inducible factor 2A promotes myocardial ischemia tolerance through induction of epidermal growth factor, amphiregulin. Here, the authors hypothesized that hypoxia-inducible factor 2A may enhance epidermal growth factor receptor 1 (ERBB1) expression in the myocardium that could interface between growth factors and its effect on providing tolerance to ischemia and reperfusion injury. METHODS: Human myocardial tissues were obtained from ischemic heart disease patients and normal control patients to compare ERBB1 expression. Myocyte-specific Hif2a or ErbB1 knockout mice were generated to observe the effect of Hif2a knockdown in regulating ERBB1 expression and to examine the role of ERBB1 during myocardial ischemia and reperfusion injury. RESULTS: Initial studies of myocardial tissues from patients with ischemic heart disease showed increased ERBB1 protein (1.12 ± 0.24 vs. 13.01 ± 2.20, P < 0.001). In contrast, ERBB1 transcript was unchanged. Studies using short hairpin RNA repression of Hif2A or Hif2a Myosin Cre+ mice directly implicated hypoxia-inducible factor 2A in ERBB1 protein induction during hypoxia or after myocardial ischemia, respectively. Repression of RNA-binding protein 4 abolished hypoxia-inducible factor 2A-dependent induction of ERBB1 protein. Moreover, ErbB1 Myosin Cre+ mice experienced larger infarct sizes (22.46 ± 4.06 vs. 46.14 ± 1.81, P < 0.001) and could not be rescued via amphiregulin treatment. CONCLUSIONS: These findings suggest that hypoxia-inducible factor 2A promotes transcription-independent induction of ERBB1 protein and implicates epidermal growth factor signaling in protection from myocardial ischemia and reperfusion injury.
BACKGROUND: During myocardial ischemia, hypoxia-inducible factors are stabilized and provide protection from ischemia and reperfusion injury. Recent studies show that myocyte-specific hypoxia-inducible factor 2A promotes myocardial ischemia tolerance through induction of epidermal growth factor, amphiregulin. Here, the authors hypothesized that hypoxia-inducible factor 2A may enhance epidermal growth factor receptor 1 (ERBB1) expression in the myocardium that could interface between growth factors and its effect on providing tolerance to ischemia and reperfusion injury. METHODS:Human myocardial tissues were obtained from ischemic heart diseasepatients and normal control patients to compare ERBB1 expression. Myocyte-specific Hif2a or ErbB1 knockout mice were generated to observe the effect of Hif2a knockdown in regulating ERBB1 expression and to examine the role of ERBB1 during myocardial ischemia and reperfusion injury. RESULTS: Initial studies of myocardial tissues from patients with ischemic heart disease showed increased ERBB1 protein (1.12 ± 0.24 vs. 13.01 ± 2.20, P < 0.001). In contrast, ERBB1 transcript was unchanged. Studies using short hairpin RNA repression of Hif2A or Hif2a Myosin Cre+ mice directly implicated hypoxia-inducible factor 2A in ERBB1 protein induction during hypoxia or after myocardial ischemia, respectively. Repression of RNA-binding protein 4 abolished hypoxia-inducible factor 2A-dependent induction of ERBB1 protein. Moreover, ErbB1 Myosin Cre+ mice experienced larger infarct sizes (22.46 ± 4.06 vs. 46.14 ± 1.81, P < 0.001) and could not be rescued via amphiregulin treatment. CONCLUSIONS: These findings suggest that hypoxia-inducible factor 2A promotes transcription-independent induction of ERBB1 protein and implicates epidermal growth factor signaling in protection from myocardial ischemia and reperfusion injury.
Authors: D W Threadgill; A A Dlugosz; L A Hansen; T Tennenbaum; U Lichti; D Yee; C LaMantia; T Mourton; K Herrup; R C Harris Journal: Science Date: 1995-07-14 Impact factor: 47.728
Authors: Mohammad A Helwani; Amit Amin; Paul Lavigne; Srikar Rao; Shari Oesterreich; Eslam Samaha; Jamie C Brown; Peter Nagele Journal: Anesthesiology Date: 2018-06 Impact factor: 7.892
Authors: Tobias Eckle; Katherine Hartmann; Stephanie Bonney; Susan Reithel; Michel Mittelbronn; Lori A Walker; Brian D Lowes; Jun Han; Christoph H Borchers; Peter M Buttrick; Douglas J Kominsky; Sean P Colgan; Holger K Eltzschig Journal: Nat Med Date: 2012-04-15 Impact factor: 53.440
Authors: Mathias Munk; Ashfaque Ahmed Memon; Jens Peter Goetze; Lars Bo Nielsen; Ebba Nexo; Boe Sandahl Sorensen Journal: PLoS One Date: 2012-07-05 Impact factor: 3.240
Authors: Shuchi Guo; Ama Dedo Okyere; Erin McEachern; Joshua L Strong; Rhonda L Carter; Viren C Patwa; Toby P Thomas; Melissa Landy; Jianliang Song; Ana Maria Lucchese; Thomas G Martin; Erhe Gao; Sudarsan Rajan; Jonathan A Kirk; Walter J Koch; Joseph Y Cheung; Douglas G Tilley Journal: Cardiovasc Res Date: 2022-03-25 Impact factor: 13.081
Authors: Jiwen Li; Catharina Conrad; Tingting W Mills; Nathaniel K Berg; Boyun Kim; Wei Ruan; Jae W Lee; Xu Zhang; Xiaoyi Yuan; Holger K Eltzschig Journal: J Exp Med Date: 2021-06-07 Impact factor: 14.307
Authors: Xiaoyi Yuan; Tingting Mills; Marie-Francoise Doursout; Scott E Evans; Marcos F Vidal Melo; Holger K Eltzschig Journal: Front Pharmacol Date: 2022-07-15 Impact factor: 5.988
Authors: Ka Lin Heck-Swain; Jiwen Li; Wei Ruan; Xiaoyi Yuan; Yanyu Wang; Michael Koeppen; Holger K Eltzschig Journal: Front Cardiovasc Med Date: 2022-09-28